Skip to content

High-throughput protein profiling for detecting colorectal cancer protein expression and prognosis

High-throughput protein profiling for detecting colorectal cancer protein expression and prognosis

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023543
Enrollment
Unknown
Registered
2019-06-01
Start date
2019-05-24
Completion date
Unknown
Last updated
2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Gold Standard:1. physical examination - digital rectal examination
2. laboratory examination - blood routine, fecal occult blood test
3. imaging examination - X-ray angiography, ultrasound
4. endoscopy - rectal sigmoidoscopy
5. clinical outcomes The gold standard is histopathology.
Index test:Disease&#32
or&#32
peripheral&#32
protein&#32
and&#32

Sponsors

Second Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Disease group inclusion criteria: 1. Aged greater than 18 years old, male or female; 2. Patients with colorectal cancer diagnosed by histopathological examination, or colorectal polyps, adenomas (high-grade intraepithelial neoplasia); 3. Acceptable root surgery; 4. A written informed consent form signed by the person or his legal representative; Healthy control group inclusion criteria: healthy people matched with the age of the disease group, no history of cancer, self-reported health.

Exclusion criteria

Exclusion criteria: 1. According to the patient's past history, suspected or indeed have a history of alcohol and drug abuse; 2. Intellectual or mental disorders, unable to cooperate with research; 3. Cannot cooperate or be lost to follow-up during follow-up; 4. Reluctant to undergo colonoscopy; 5. There are other serious diseases of the digestive tract, such as Crohn's disease, ulcerative colitis, etc.; 6. Serious heart, liver, lung, kidney, blood, endocrine system diseases; 7. pregnant women, lactating women or women of childbearing age who are ready to conceive; 8. The researcher believes that there is any situation that is not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Proteomics;SPF;Survival time;

Secondary

MeasureTime frame
Tumor metastasis site;Tumor pathological type;

Countries

China

Contacts

Public ContactShu Zheng

Second Affiliated Hospital of Zhejiang University School of Medicine

zhengshu@zju.edu.cn+86 13600528729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026